ArticleThe Journal of investigative dermatology2018
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Article in The Journal of investigative dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 68 citations in OpenAlex.
- Decoding the impact of nsSNP variants on BCL6 function through integrated computational analysis.Current research in structural biology · 2026Article
- RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Association of Secondary Primary Malignancies in Cutaneous Lymphoma: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Unveiling Primary Cutaneous B-Cell Lymphomas: New Insights into Diagnosis and Treatment Strategies.Cancers · 2025Review
- A rare case of CD20JAAD case reports · 2024Article
- Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma.Annals of hematology · 2023Article
- Primary cutaneous diffuse large B-cell lymphoma, leg type, presenting as subcutaneous nodules: Case series and comparison of treatment outcomes.JAAD case reports · 2023Article
- Review
- Primary Cutaneous B-Cell Lymphomas with Large Cell Morphology: A Practical Review.International journal of molecular sciences · 2023Review
- Cutaneous Lymphoma and Antibody-Directed Therapies.Antibodies (Basel, Switzerland) · 2023Review
- Disease-Defining Molecular Features of Primary Cutaneous B-Cell Lymphomas: Implications for Classification and Treatment.The Journal of investigative dermatology · 2023Review
- Molecular classification and therapeutics in diffuse large B-cell lymphoma.Frontiers in molecular biosciences · 2023Review
- Article
- Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas.American journal of clinical dermatology · 2022Review
- Integrative diagnosis of primary cutaneous large B-cell lymphomas supports the relevance of cell of origin profiling.PloS one · 2022Article
- Article
- Review
- Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features.Blood advances · 2021Article
- The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins.International journal of molecular sciences · 2021Review
- Molecular Pathogenesis ofFrontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 2 countries.
Funding
Abstract
Cutaneous diffuse large B-cell lymphomas (DLBCLs) are aggressive lymphomas with a poor prognosis. To elucidate their genetic bases, we analyzed exome sequencing of 37 cutaneous DLBCLs, including 31 DLBCLs, leg type (DLBCL-LT) and 6 cutaneous DLBCLs-not otherwise specified (DLBCL-NOS). As reported previously, 77% of DLBCL-LT harbor NF-κB-activating MYD88 mutations. In nearly all MYD88-wild-type DLBCL-LT, we found cancer-promoting mutations that either activate the NF-κB pathway through alternative genes (NFKBIE or REL) or activate other canonical cancer pathways (BRAF, MED12, PIK3R1, and STAT3). After NF-κB, the second most commonly mutated pathway putatively enables immune evasion via mutations predicted to downregulate antigen processing (B2M, CIITA, HLA) or T-cell co-stimulation (CD58). DLBCL-LT have little genetic overlap with the genetically heterogeneous DLBCL-NOS. Instead, they resemble primary central nervous system and testicular large B-cell lymphomas (primary central nervous system lymphomas and primary testicular lymphomas). Like primary central nervous system lymphomas/primary testicular lymphomas, 40% of DLBCL-LT (vs. 0% of DLBCLs-not otherwise specified) harbored PDL1/PDL2 translocations, which lead to overexpression of PD-L1 or PD-L2 in 50% of the cases. Collectively, these data broaden our understanding of cutaneous DLBCLs and suggest novel therapeutic approaches (e.g., BRAF or PI3K inhibitors). Additionally, they suggest novel treatment paradigms, wherein DLBCL-LT can be targeted with strategies (e.g., immune checkpoint blockers) currently being developed for genomically similar primary central nervous system lymphomas/primary testicular lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.